Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 1,142 shares at $3.01 ($3K) on 2012-12-26, disclosed to the SEC on 2012-12-26.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-20 | $23K | — | Filing → |